Logo image
Plausible Role of Asthma Biological Modifiers in the Treatment of Eosinophilic Esophagitis
Journal article   Open access   Peer reviewed

Plausible Role of Asthma Biological Modifiers in the Treatment of Eosinophilic Esophagitis

Timothy C. Olsen, Robert A. Promisloff, Denise DeCostanzo, Gang He and Anthony M. Szema
Curēus (Palo Alto, CA), v 13(7)
18 Jul 2021
PMID: 34422489
url
https://doi.org/10.7759/cureus.16460View
Published, Version of Record (VoR)CC BY V4.0 Open

Abstract

General & Internal Medicine Life Sciences & Biomedicine Medicine, General & Internal Science & Technology
Eosinophilic esophagitis (EoE) is a T-helper type-2 (Th2/T2) cell-mediated disease characterized by 15 or more eosinophils per high-powered esophageal biopsy microscopy field (eos/hpf), excluding other causes. EoE is often clinically characterized by symptoms such as dysphagia, nausea, food impaction, and chest pain that do not respond to antacids. Two-thirds of patients are unresponsive to proton pump inhibitors (PPIs). Steroids may be effective but pose long-term health risks and can lose efficacy in patients with serum eosinophilia greater than 1,500 cells/mu L. Because EoE is not IgE- mediated, allergy skin testing for food may benefit a subset of patients. These therapies have shortcomings, which necessitate further investigation. Herein, we report a patient successfully treated with benralizumab (anti-IL-5Ra), demonstrating a potential solution to the lack of effective treatments for EoE.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Gastroenterology & Hepatology
Logo image